State of Wyoming Buys 15,284 Shares of CareDx, Inc. $CDNA

State of Wyoming lifted its stake in CareDx, Inc. (NASDAQ:CDNA) by 185.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,537 shares of the company’s stock after buying an additional 15,284 shares during the period. State of Wyoming’s holdings in CareDx were worth $409,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Quarry LP bought a new stake in CareDx in the fourth quarter valued at approximately $25,000. Meeder Asset Management Inc. bought a new position in shares of CareDx in the fourth quarter worth approximately $79,000. Quantbot Technologies LP bought a new position in shares of CareDx in the third quarter worth approximately $89,000. CWM LLC increased its stake in shares of CareDx by 119.1% in the fourth quarter. CWM LLC now owns 7,407 shares of the company’s stock worth $140,000 after buying an additional 4,026 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in CareDx by 120.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after buying an additional 4,160 shares during the last quarter.

Insider Activity at CareDx

In other news, CEO John Walter Hanna, Jr. sold 39,900 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $29.24, for a total value of $1,166,676.00. Following the transaction, the chief executive officer owned 661,959 shares in the company, valued at approximately $19,355,681.16. This represents a 5.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 12,103 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $23.11, for a total transaction of $279,700.33. Following the sale, the director directly owned 36,686 shares of the company’s stock, valued at $847,813.46. This trade represents a 24.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 78,936 shares of company stock worth $2,093,708. Insiders own 2.40% of the company’s stock.

CareDx Price Performance

CDNA opened at $37.14 on Monday. The stock has a 50-day moving average price of $26.91 and a 200-day moving average price of $21.94. The firm has a market cap of $1.92 billion, a PE ratio of -232.12 and a beta of 2.43. CareDx, Inc. has a 1 year low of $11.26 and a 1 year high of $40.47.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.23. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The company had revenue of $117.70 million for the quarter, compared to analysts’ expectations of $102.03 million. CareDx’s revenue was up 39.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.09 EPS. As a group, sell-side analysts anticipate that CareDx, Inc. will post 0.22 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on CDNA. Craig Hallum reissued a “hold” rating and set a $35.00 price target on shares of CareDx in a research report on Thursday, July 16th. BTIG Research upped their price objective on shares of CareDx from $28.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. William Blair upgraded shares of CareDx to a “hold” rating in a report on Thursday, July 16th. Finally, Weiss Ratings cut CareDx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $33.67.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.